Small-Cap Pharma Stock in Focus: Sudarshan Pharma Jumps 4% After 9.50% Stake Buy Plan in US Biotech Firm

Sudarshan Pharma Industries is attracting investor attention in Monday's trading session after the small-cap pharmaceutical company announced plans to acquire a 9.50% stake in US-based MedTherapy Biotechnology Inc. The proposed investment is aimed at strengthening Sudarshan Pharma's international presence and could provide the company with an entry point into the American biotechnology market.

Sudarshan Pharma Share Price Today

Sudarshan Pharma Industries Ltd shares were trading at Rs 40.85 on September 7, 2026, marking a rise of 3.63%, or Rs 1.43, during the session. The stock opened at Rs 40.25 and touched an intraday high of Rs 41.39. The day's low stood at Rs 40.25.

Small-Cap Pharma Stock to Acquire 9.50% Stake in US-Based MedTherapy Biotechnology

The company's board approved the proposed transaction, which was disclosed in an exchange filing on September 5. Sudarshan Pharma shares closed nearly 1% higher at Rs 39.42 on Friday. With a market capitalisation of around Rs 984 crore as of September 4, the company falls within the small-cap segment.

Sudarshan Pharma plans to acquire around 24.24 lakh equity shares in MedTherapy Biotechnology, representing 9.50% of the company's total issued and outstanding share capital. The transaction will be completed through a cash investment denominated in US dollars.

The final purchase consideration will depend on the valuation applicable to MedTherapy at the time of the transaction. Sudarshan Pharma expects to complete the acquisition by March 31, 2027, subject to regulatory requirements and other conditions.

In addition to the company's proposed investment, Chairman and Managing Director (MD) Hemal Mehta and Joint MD Sachin Mehta are also planning separate investments in MedTherapy. Both promoters are expected to acquire a 1.50% stake each in the biotechnology company.

The proposed overseas investment will be carried out under the applicable provisions of the Foreign Exchange Management Act and India's overseas investment framework. The company said the transaction would fall under the Reserve Bank of India's automatic route, provided all relevant conditions are fulfilled.

What Does MedTherapy Biotechnology Do?

MedTherapy Biotechnology is a Boston-based company operating in the specialised field of cancer cell and gene therapy. Its business includes work related to CAR-T cell therapy, an advanced form of cancer treatment that uses specially modified immune cells to fight cancer.

The company operates as an integrated contract development and manufacturing organisation for CAR-T cell therapies. It has a commercial-scale GMP manufacturing facility in New Delhi and a technology development centre in Boston.

For Sudarshan Pharma, the proposed minority investment could help create new opportunities in the US healthcare and biotechnology market. The company expects to benefit from MedTherapy's existing customer relationships, contracts and distribution network while also exploring opportunities in new products and services.

However, the acquisition does not give Sudarshan Pharma control over MedTherapy. The proposed 9.50% stake is a minority holding, meaning the Indian company will gain an investment interest in the business without taking over its operations.

Multibagger Small-Cap Pharma Stock Delivers Strong Returns

Sudarshan Pharma shares have delivered substantial gains across several periods. The stock has risen more than 15% over the past month and over 52% during the last six months. It has also gained more than 46% so far this year.

Over the past three years, the small-cap pharma stock has surged around 369%, generating multibagger returns for long-term shareholders. The sharp rally could keep the stock on traders' radar, particularly following the announcement of the proposed international investment.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.